nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP2J2—Cholecalciferol—osteoporosis	0.48	0.665	CbGbCtD
Rivaroxaban—ABCB1—Ethinyl Estradiol—osteoporosis	0.0284	0.0394	CbGbCtD
Rivaroxaban—CYP3A5—Estradiol—osteoporosis	0.0281	0.039	CbGbCtD
Rivaroxaban—CYP3A4—Estropipate—osteoporosis	0.0264	0.0366	CbGbCtD
Rivaroxaban—CYP3A4—Calcitriol—osteoporosis	0.0264	0.0366	CbGbCtD
Rivaroxaban—CYP3A4—Ergocalciferol—osteoporosis	0.0211	0.0293	CbGbCtD
Rivaroxaban—ABCB1—Conjugated Estrogens—osteoporosis	0.0208	0.0289	CbGbCtD
Rivaroxaban—ABCB1—Estradiol—osteoporosis	0.0183	0.0254	CbGbCtD
Rivaroxaban—CYP3A4—Raloxifene—osteoporosis	0.0176	0.0244	CbGbCtD
Rivaroxaban—CYP3A4—Ethinyl Estradiol—osteoporosis	0.017	0.0236	CbGbCtD
Rivaroxaban—CYP3A4—Cholecalciferol—osteoporosis	0.0136	0.0189	CbGbCtD
Rivaroxaban—CYP3A4—Conjugated Estrogens—osteoporosis	0.0125	0.0173	CbGbCtD
Rivaroxaban—CYP3A4—Estradiol—osteoporosis	0.011	0.0152	CbGbCtD
Rivaroxaban—F10—Common Pathway—FGA—osteoporosis	0.00322	0.056	CbGpPWpGaD
Rivaroxaban—F10—Common Pathway—FGB—osteoporosis	0.00293	0.051	CbGpPWpGaD
Rivaroxaban—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00281	0.049	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—FGA—osteoporosis	0.00274	0.0477	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—FGB—osteoporosis	0.0025	0.0434	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—FGA—osteoporosis	0.0022	0.0383	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—FGB—osteoporosis	0.002	0.0348	CbGpPWpGaD
Rivaroxaban—F10—Formation of Fibrin Clot (Clotting Cascade)—FGA—osteoporosis	0.00185	0.0322	CbGpPWpGaD
Rivaroxaban—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00173	0.0302	CbGpPWpGaD
Rivaroxaban—F10—Formation of Fibrin Clot (Clotting Cascade)—FGB—osteoporosis	0.00168	0.0293	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00164	0.0286	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00162	0.0282	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00133	0.0232	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—FGB—osteoporosis	0.00113	0.0197	CbGpPWpGaD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CYP19A1—osteoporosis	0.00107	0.0186	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000862	0.015	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000851	0.0148	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000812	0.0141	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP27A1—osteoporosis	0.000707	0.0123	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000699	0.0122	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP27A1—osteoporosis	0.000697	0.0121	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—WDR1—osteoporosis	0.000603	0.0105	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—PKM—osteoporosis	0.000576	0.01	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000518	0.00902	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—CAP1—osteoporosis	0.000477	0.0083	CbGpPWpGaD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000473	0.00823	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000473	0.00822	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000467	0.00812	CbGpPWpGaD
Rivaroxaban—ABCB1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000449	0.00782	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000448	0.00779	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.00042	0.00731	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TUBA1B—osteoporosis	0.000402	0.007	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CCT2—osteoporosis	0.000393	0.00684	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000383	0.00667	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MGLL—osteoporosis	0.000379	0.00659	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP19A1—osteoporosis	0.000371	0.00646	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP19A1—osteoporosis	0.000366	0.00637	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000348	0.00606	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ANXA2—osteoporosis	0.000346	0.00603	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PLEK—osteoporosis	0.000346	0.00603	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000339	0.00591	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—TUBA1B—osteoporosis	0.000334	0.00582	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TLN1—osteoporosis	0.000299	0.0052	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VCL—osteoporosis	0.000295	0.00513	CbGpPWpGaD
Rivaroxaban—Gastrointestinal pain—Ibandronate—osteoporosis	0.000283	0.00128	CcSEcCtD
Rivaroxaban—Back pain—Conjugated Estrogens—osteoporosis	0.000283	0.00128	CcSEcCtD
Rivaroxaban—Urticaria—Alendronate—osteoporosis	0.000283	0.00128	CcSEcCtD
Rivaroxaban—Epistaxis—Estradiol—osteoporosis	0.000283	0.00128	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Zoledronate—osteoporosis	0.000282	0.00127	CcSEcCtD
Rivaroxaban—Abdominal pain—Alendronate—osteoporosis	0.000281	0.00127	CcSEcCtD
Rivaroxaban—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000281	0.00127	CcSEcCtD
Rivaroxaban—Sinusitis—Estradiol—osteoporosis	0.000281	0.00127	CcSEcCtD
Rivaroxaban—Shock—Risedronate—osteoporosis	0.000281	0.00127	CcSEcCtD
Rivaroxaban—Anaemia—Zoledronate—osteoporosis	0.000281	0.00127	CcSEcCtD
Rivaroxaban—Nervous system disorder—Risedronate—osteoporosis	0.00028	0.00126	CcSEcCtD
Rivaroxaban—Discomfort—Pamidronate—osteoporosis	0.00028	0.00126	CcSEcCtD
Rivaroxaban—Angioedema—Zoledronate—osteoporosis	0.000278	0.00125	CcSEcCtD
Rivaroxaban—Skin disorder—Risedronate—osteoporosis	0.000277	0.00125	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Calcitriol—osteoporosis	0.000277	0.00125	CcSEcCtD
Rivaroxaban—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000277	0.00482	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Raloxifene—osteoporosis	0.000277	0.00125	CcSEcCtD
Rivaroxaban—Urticaria—Ibandronate—osteoporosis	0.000275	0.00124	CcSEcCtD
Rivaroxaban—Malaise—Zoledronate—osteoporosis	0.000274	0.00124	CcSEcCtD
Rivaroxaban—Abdominal pain—Ibandronate—osteoporosis	0.000274	0.00124	CcSEcCtD
Rivaroxaban—Syncope—Zoledronate—osteoporosis	0.000272	0.00123	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Pamidronate—osteoporosis	0.000271	0.00123	CcSEcCtD
Rivaroxaban—Oedema—Pamidronate—osteoporosis	0.000271	0.00123	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000271	0.00472	CbGpPWpGaD
Rivaroxaban—Haemoglobin—Estradiol—osteoporosis	0.00027	0.00122	CcSEcCtD
Rivaroxaban—Infection—Pamidronate—osteoporosis	0.00027	0.00122	CcSEcCtD
Rivaroxaban—Urticaria—Calcitriol—osteoporosis	0.000269	0.00122	CcSEcCtD
Rivaroxaban—Haemorrhage—Estradiol—osteoporosis	0.000269	0.00121	CcSEcCtD
Rivaroxaban—Hepatitis—Estradiol—osteoporosis	0.000269	0.00121	CcSEcCtD
Rivaroxaban—Abdominal pain—Calcitriol—osteoporosis	0.000268	0.00121	CcSEcCtD
Rivaroxaban—Angioedema—Conjugated Estrogens—osteoporosis	0.000267	0.00121	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—RPL24—osteoporosis	0.000267	0.00465	CbGpPWpGaD
Rivaroxaban—Shock—Pamidronate—osteoporosis	0.000267	0.00121	CcSEcCtD
Rivaroxaban—Loss of consciousness—Zoledronate—osteoporosis	0.000267	0.00121	CcSEcCtD
Rivaroxaban—Hypersensitivity—Estropipate—osteoporosis	0.000266	0.0012	CcSEcCtD
Rivaroxaban—Nervous system disorder—Pamidronate—osteoporosis	0.000266	0.0012	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Estradiol—osteoporosis	0.000266	0.0012	CcSEcCtD
Rivaroxaban—Vomiting—Etidronic acid—osteoporosis	0.000266	0.0012	CcSEcCtD
Rivaroxaban—Tachycardia—Pamidronate—osteoporosis	0.000265	0.0012	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Estradiol—osteoporosis	0.000264	0.00119	CcSEcCtD
Rivaroxaban—Urethral disorder—Estradiol—osteoporosis	0.000264	0.00119	CcSEcCtD
Rivaroxaban—Rash—Etidronic acid—osteoporosis	0.000263	0.00119	CcSEcCtD
Rivaroxaban—Dermatitis—Etidronic acid—osteoporosis	0.000263	0.00119	CcSEcCtD
Rivaroxaban—Syncope—Conjugated Estrogens—osteoporosis	0.000262	0.00118	CcSEcCtD
Rivaroxaban—Hypersensitivity—Alendronate—osteoporosis	0.000262	0.00118	CcSEcCtD
Rivaroxaban—Headache—Etidronic acid—osteoporosis	0.000262	0.00118	CcSEcCtD
Rivaroxaban—Asthenia—Estropipate—osteoporosis	0.000259	0.00117	CcSEcCtD
Rivaroxaban—Chest pain—Zoledronate—osteoporosis	0.000259	0.00117	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000258	0.00449	CbGpPWpGaD
Rivaroxaban—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000257	0.00116	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000257	0.00116	CcSEcCtD
Rivaroxaban—Pruritus—Estropipate—osteoporosis	0.000256	0.00115	CcSEcCtD
Rivaroxaban—Discomfort—Zoledronate—osteoporosis	0.000256	0.00115	CcSEcCtD
Rivaroxaban—Asthenia—Alendronate—osteoporosis	0.000255	0.00115	CcSEcCtD
Rivaroxaban—Hypersensitivity—Ibandronate—osteoporosis	0.000255	0.00115	CcSEcCtD
Rivaroxaban—Dyspnoea—Risedronate—osteoporosis	0.000255	0.00115	CcSEcCtD
Rivaroxaban—Erythema multiforme—Estradiol—osteoporosis	0.000254	0.00115	CcSEcCtD
Rivaroxaban—Hypotension—Pamidronate—osteoporosis	0.000254	0.00115	CcSEcCtD
Rivaroxaban—Dry mouth—Zoledronate—osteoporosis	0.000253	0.00114	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000253	0.00114	CcSEcCtD
Rivaroxaban—Fatigue—Ethinyl Estradiol—osteoporosis	0.000253	0.00114	CcSEcCtD
Rivaroxaban—Pruritus—Alendronate—osteoporosis	0.000252	0.00114	CcSEcCtD
Rivaroxaban—Dyspepsia—Risedronate—osteoporosis	0.000251	0.00114	CcSEcCtD
Rivaroxaban—Eye disorder—Estradiol—osteoporosis	0.000251	0.00114	CcSEcCtD
Rivaroxaban—Constipation—Ethinyl Estradiol—osteoporosis	0.00025	0.00113	CcSEcCtD
Rivaroxaban—Hypersensitivity—Calcitriol—osteoporosis	0.00025	0.00113	CcSEcCtD
Rivaroxaban—Cardiac disorder—Estradiol—osteoporosis	0.00025	0.00113	CcSEcCtD
Rivaroxaban—Chest pain—Conjugated Estrogens—osteoporosis	0.000249	0.00112	CcSEcCtD
Rivaroxaban—Asthenia—Ibandronate—osteoporosis	0.000249	0.00112	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000248	0.00432	CbGpPWpGaD
Rivaroxaban—Nausea—Etidronic acid—osteoporosis	0.000248	0.00112	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Zoledronate—osteoporosis	0.000248	0.00112	CcSEcCtD
Rivaroxaban—Oedema—Zoledronate—osteoporosis	0.000248	0.00112	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000247	0.00112	CcSEcCtD
Rivaroxaban—Diarrhoea—Estropipate—osteoporosis	0.000247	0.00112	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Risedronate—osteoporosis	0.000247	0.00111	CcSEcCtD
Rivaroxaban—Infection—Zoledronate—osteoporosis	0.000246	0.00111	CcSEcCtD
Rivaroxaban—Fatigue—Risedronate—osteoporosis	0.000246	0.00111	CcSEcCtD
Rivaroxaban—F10—Hemostasis—RAP1A—osteoporosis	0.000246	0.00428	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000245	0.00427	CbGpPWpGaD
Rivaroxaban—Pruritus—Ibandronate—osteoporosis	0.000245	0.00111	CcSEcCtD
Rivaroxaban—Pain—Risedronate—osteoporosis	0.000244	0.0011	CcSEcCtD
Rivaroxaban—Constipation—Risedronate—osteoporosis	0.000244	0.0011	CcSEcCtD
Rivaroxaban—Angiopathy—Estradiol—osteoporosis	0.000244	0.0011	CcSEcCtD
Rivaroxaban—Shock—Zoledronate—osteoporosis	0.000244	0.0011	CcSEcCtD
Rivaroxaban—Diarrhoea—Alendronate—osteoporosis	0.000244	0.0011	CcSEcCtD
Rivaroxaban—Asthenia—Calcitriol—osteoporosis	0.000243	0.0011	CcSEcCtD
Rivaroxaban—Nervous system disorder—Zoledronate—osteoporosis	0.000243	0.0011	CcSEcCtD
Rivaroxaban—Immune system disorder—Estradiol—osteoporosis	0.000243	0.0011	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Estradiol—osteoporosis	0.000242	0.00109	CcSEcCtD
Rivaroxaban—Dyspnoea—Pamidronate—osteoporosis	0.000242	0.00109	CcSEcCtD
Rivaroxaban—Tachycardia—Zoledronate—osteoporosis	0.000242	0.00109	CcSEcCtD
Rivaroxaban—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000241	0.00109	CcSEcCtD
Rivaroxaban—Skin disorder—Zoledronate—osteoporosis	0.000241	0.00109	CcSEcCtD
Rivaroxaban—Pruritus—Calcitriol—osteoporosis	0.00024	0.00108	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00024	0.00108	CcSEcCtD
Rivaroxaban—Diarrhoea—Raloxifene—osteoporosis	0.000239	0.00108	CcSEcCtD
Rivaroxaban—Dyspepsia—Pamidronate—osteoporosis	0.000239	0.00108	CcSEcCtD
Rivaroxaban—Dizziness—Estropipate—osteoporosis	0.000239	0.00108	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000239	0.00108	CcSEcCtD
Rivaroxaban—Oedema—Conjugated Estrogens—osteoporosis	0.000239	0.00108	CcSEcCtD
Rivaroxaban—Infection—Conjugated Estrogens—osteoporosis	0.000237	0.00107	CcSEcCtD
Rivaroxaban—Diarrhoea—Ibandronate—osteoporosis	0.000237	0.00107	CcSEcCtD
Rivaroxaban—Dizziness—Alendronate—osteoporosis	0.000235	0.00106	CcSEcCtD
Rivaroxaban—Shock—Conjugated Estrogens—osteoporosis	0.000235	0.00106	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—TLN1—osteoporosis	0.000235	0.00409	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000234	0.00106	CcSEcCtD
Rivaroxaban—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000234	0.00106	CcSEcCtD
Rivaroxaban—Fatigue—Pamidronate—osteoporosis	0.000234	0.00106	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Risedronate—osteoporosis	0.000234	0.00105	CcSEcCtD
Rivaroxaban—Tachycardia—Conjugated Estrogens—osteoporosis	0.000233	0.00105	CcSEcCtD
Rivaroxaban—Urticaria—Ethinyl Estradiol—osteoporosis	0.000233	0.00105	CcSEcCtD
Rivaroxaban—Pain—Pamidronate—osteoporosis	0.000232	0.00105	CcSEcCtD
Rivaroxaban—Constipation—Pamidronate—osteoporosis	0.000232	0.00105	CcSEcCtD
Rivaroxaban—Diarrhoea—Calcitriol—osteoporosis	0.000232	0.00105	CcSEcCtD
Rivaroxaban—Skin disorder—Conjugated Estrogens—osteoporosis	0.000232	0.00105	CcSEcCtD
Rivaroxaban—Hypotension—Zoledronate—osteoporosis	0.000232	0.00105	CcSEcCtD
Rivaroxaban—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000232	0.00105	CcSEcCtD
Rivaroxaban—Dizziness—Raloxifene—osteoporosis	0.000231	0.00105	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000231	0.00402	CbGpPWpGaD
Rivaroxaban—Vomiting—Estropipate—osteoporosis	0.00023	0.00104	CcSEcCtD
Rivaroxaban—Dizziness—Ibandronate—osteoporosis	0.000229	0.00103	CcSEcCtD
Rivaroxaban—Rash—Estropipate—osteoporosis	0.000228	0.00103	CcSEcCtD
Rivaroxaban—Dermatitis—Estropipate—osteoporosis	0.000228	0.00103	CcSEcCtD
Rivaroxaban—Urticaria—Risedronate—osteoporosis	0.000227	0.00102	CcSEcCtD
Rivaroxaban—Back pain—Estradiol—osteoporosis	0.000226	0.00102	CcSEcCtD
Rivaroxaban—Headache—Estropipate—osteoporosis	0.000226	0.00102	CcSEcCtD
Rivaroxaban—Vomiting—Alendronate—osteoporosis	0.000226	0.00102	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—REN—osteoporosis	0.000226	0.00393	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Risedronate—osteoporosis	0.000226	0.00102	CcSEcCtD
Rivaroxaban—Muscle spasms—Estradiol—osteoporosis	0.000225	0.00102	CcSEcCtD
Rivaroxaban—Rash—Alendronate—osteoporosis	0.000224	0.00101	CcSEcCtD
Rivaroxaban—Dermatitis—Alendronate—osteoporosis	0.000224	0.00101	CcSEcCtD
Rivaroxaban—Feeling abnormal—Pamidronate—osteoporosis	0.000224	0.00101	CcSEcCtD
Rivaroxaban—F10—Hemostasis—FGA—osteoporosis	0.000223	0.00388	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—POMC—osteoporosis	0.000223	0.00388	CbGpPWpGaD
Rivaroxaban—Hypotension—Conjugated Estrogens—osteoporosis	0.000223	0.00101	CcSEcCtD
Rivaroxaban—Headache—Alendronate—osteoporosis	0.000223	0.00101	CcSEcCtD
Rivaroxaban—Vomiting—Raloxifene—osteoporosis	0.000223	0.00101	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Pamidronate—osteoporosis	0.000222	0.001	CcSEcCtD
Rivaroxaban—Dyspnoea—Zoledronate—osteoporosis	0.000221	0.000999	CcSEcCtD
Rivaroxaban—Rash—Raloxifene—osteoporosis	0.000221	0.000997	CcSEcCtD
Rivaroxaban—Dermatitis—Raloxifene—osteoporosis	0.00022	0.000996	CcSEcCtD
Rivaroxaban—Vomiting—Ibandronate—osteoporosis	0.00022	0.000995	CcSEcCtD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00022	0.00383	CbGpPWpGaD
Rivaroxaban—Headache—Raloxifene—osteoporosis	0.000219	0.00099	CcSEcCtD
Rivaroxaban—Rash—Ibandronate—osteoporosis	0.000218	0.000987	CcSEcCtD
Rivaroxaban—Dermatitis—Ibandronate—osteoporosis	0.000218	0.000986	CcSEcCtD
Rivaroxaban—Dyspepsia—Zoledronate—osteoporosis	0.000218	0.000986	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000217	0.00378	CbGpPWpGaD
Rivaroxaban—Ill-defined disorder—Estradiol—osteoporosis	0.000217	0.000981	CcSEcCtD
Rivaroxaban—Headache—Ibandronate—osteoporosis	0.000217	0.00098	CcSEcCtD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000217	0.00378	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000216	0.000975	CcSEcCtD
Rivaroxaban—Vomiting—Calcitriol—osteoporosis	0.000216	0.000974	CcSEcCtD
Rivaroxaban—Nausea—Estropipate—osteoporosis	0.000215	0.000969	CcSEcCtD
Rivaroxaban—Abdominal pain—Pamidronate—osteoporosis	0.000215	0.000969	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000214	0.000967	CcSEcCtD
Rivaroxaban—Angioedema—Estradiol—osteoporosis	0.000214	0.000966	CcSEcCtD
Rivaroxaban—Rash—Calcitriol—osteoporosis	0.000214	0.000966	CcSEcCtD
Rivaroxaban—Fatigue—Zoledronate—osteoporosis	0.000214	0.000966	CcSEcCtD
Rivaroxaban—Dermatitis—Calcitriol—osteoporosis	0.000214	0.000965	CcSEcCtD
Rivaroxaban—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000213	0.000961	CcSEcCtD
Rivaroxaban—Headache—Calcitriol—osteoporosis	0.000213	0.00096	CcSEcCtD
Rivaroxaban—Constipation—Zoledronate—osteoporosis	0.000212	0.000958	CcSEcCtD
Rivaroxaban—Pain—Zoledronate—osteoporosis	0.000212	0.000958	CcSEcCtD
Rivaroxaban—Nausea—Alendronate—osteoporosis	0.000211	0.000955	CcSEcCtD
Rivaroxaban—Malaise—Estradiol—osteoporosis	0.000211	0.000954	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—FDPS—osteoporosis	0.00021	0.00366	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PKM—osteoporosis	0.00021	0.00366	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Risedronate—osteoporosis	0.00021	0.00095	CcSEcCtD
Rivaroxaban—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00021	0.000949	CcSEcCtD
Rivaroxaban—Asthenia—Ethinyl Estradiol—osteoporosis	0.00021	0.000949	CcSEcCtD
Rivaroxaban—Syncope—Estradiol—osteoporosis	0.00021	0.000948	CcSEcCtD
Rivaroxaban—Nausea—Raloxifene—osteoporosis	0.000208	0.000939	CcSEcCtD
Rivaroxaban—Pruritus—Ethinyl Estradiol—osteoporosis	0.000207	0.000936	CcSEcCtD
Rivaroxaban—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000207	0.00361	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000206	0.000931	CcSEcCtD
Rivaroxaban—Fatigue—Conjugated Estrogens—osteoporosis	0.000206	0.00093	CcSEcCtD
Rivaroxaban—Nausea—Ibandronate—osteoporosis	0.000206	0.00093	CcSEcCtD
Rivaroxaban—Loss of consciousness—Estradiol—osteoporosis	0.000206	0.000929	CcSEcCtD
Rivaroxaban—Asthenia—Risedronate—osteoporosis	0.000205	0.000925	CcSEcCtD
Rivaroxaban—Feeling abnormal—Zoledronate—osteoporosis	0.000204	0.000923	CcSEcCtD
Rivaroxaban—Constipation—Conjugated Estrogens—osteoporosis	0.000204	0.000922	CcSEcCtD
Rivaroxaban—Pain—Conjugated Estrogens—osteoporosis	0.000204	0.000922	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—CYP27A1—osteoporosis	0.000204	0.00354	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—FGB—osteoporosis	0.000203	0.00353	CbGpPWpGaD
Rivaroxaban—Gastrointestinal pain—Zoledronate—osteoporosis	0.000203	0.000916	CcSEcCtD
Rivaroxaban—Pruritus—Risedronate—osteoporosis	0.000202	0.000913	CcSEcCtD
Rivaroxaban—Nausea—Calcitriol—osteoporosis	0.000201	0.00091	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000201	0.00351	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP27A1—osteoporosis	0.000201	0.0035	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.0002	0.000905	CcSEcCtD
Rivaroxaban—Hypersensitivity—Pamidronate—osteoporosis	0.0002	0.000903	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GPD2—osteoporosis	0.000199	0.00347	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PGLS—osteoporosis	0.000199	0.00347	CbGpPWpGaD
Rivaroxaban—Chest pain—Estradiol—osteoporosis	0.000199	0.0009	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000198	0.000894	CcSEcCtD
Rivaroxaban—Urticaria—Zoledronate—osteoporosis	0.000197	0.00089	CcSEcCtD
Rivaroxaban—Discomfort—Estradiol—osteoporosis	0.000197	0.00089	CcSEcCtD
Rivaroxaban—Abdominal pain—Zoledronate—osteoporosis	0.000196	0.000885	CcSEcCtD
Rivaroxaban—Diarrhoea—Risedronate—osteoporosis	0.000195	0.000883	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000195	0.000882	CcSEcCtD
Rivaroxaban—Dry mouth—Estradiol—osteoporosis	0.000195	0.000881	CcSEcCtD
Rivaroxaban—Asthenia—Pamidronate—osteoporosis	0.000195	0.00088	CcSEcCtD
Rivaroxaban—Dizziness—Ethinyl Estradiol—osteoporosis	0.000194	0.000875	CcSEcCtD
Rivaroxaban—Pruritus—Pamidronate—osteoporosis	0.000192	0.000867	CcSEcCtD
Rivaroxaban—Oedema—Estradiol—osteoporosis	0.000191	0.000863	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Estradiol—osteoporosis	0.000191	0.000863	CcSEcCtD
Rivaroxaban—Infection—Estradiol—osteoporosis	0.00019	0.000857	CcSEcCtD
Rivaroxaban—Urticaria—Conjugated Estrogens—osteoporosis	0.00019	0.000857	CcSEcCtD
Rivaroxaban—Dizziness—Risedronate—osteoporosis	0.000189	0.000853	CcSEcCtD
Rivaroxaban—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000189	0.000853	CcSEcCtD
Rivaroxaban—Shock—Estradiol—osteoporosis	0.000188	0.000849	CcSEcCtD
Rivaroxaban—Nervous system disorder—Estradiol—osteoporosis	0.000187	0.000846	CcSEcCtD
Rivaroxaban—Tachycardia—Estradiol—osteoporosis	0.000187	0.000842	CcSEcCtD
Rivaroxaban—Vomiting—Ethinyl Estradiol—osteoporosis	0.000186	0.000841	CcSEcCtD
Rivaroxaban—Diarrhoea—Pamidronate—osteoporosis	0.000186	0.000839	CcSEcCtD
Rivaroxaban—Skin disorder—Estradiol—osteoporosis	0.000186	0.000838	CcSEcCtD
Rivaroxaban—Rash—Ethinyl Estradiol—osteoporosis	0.000185	0.000834	CcSEcCtD
Rivaroxaban—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000185	0.000833	CcSEcCtD
Rivaroxaban—Headache—Ethinyl Estradiol—osteoporosis	0.000183	0.000829	CcSEcCtD
Rivaroxaban—Hypersensitivity—Zoledronate—osteoporosis	0.000183	0.000825	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—PNP—osteoporosis	0.000182	0.00318	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ATIC—osteoporosis	0.000182	0.00318	CbGpPWpGaD
Rivaroxaban—Vomiting—Risedronate—osteoporosis	0.000182	0.00082	CcSEcCtD
Rivaroxaban—Rash—Risedronate—osteoporosis	0.00018	0.000813	CcSEcCtD
Rivaroxaban—Dermatitis—Risedronate—osteoporosis	0.00018	0.000813	CcSEcCtD
Rivaroxaban—Dizziness—Pamidronate—osteoporosis	0.00018	0.000811	CcSEcCtD
Rivaroxaban—Headache—Risedronate—osteoporosis	0.000179	0.000808	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000178	0.0031	CbGpPWpGaD
Rivaroxaban—Asthenia—Zoledronate—osteoporosis	0.000178	0.000804	CcSEcCtD
Rivaroxaban—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000176	0.000795	CcSEcCtD
Rivaroxaban—Pruritus—Zoledronate—osteoporosis	0.000175	0.000792	CcSEcCtD
Rivaroxaban—Nausea—Ethinyl Estradiol—osteoporosis	0.000174	0.000786	CcSEcCtD
Rivaroxaban—Vomiting—Pamidronate—osteoporosis	0.000173	0.00078	CcSEcCtD
Rivaroxaban—Asthenia—Conjugated Estrogens—osteoporosis	0.000171	0.000774	CcSEcCtD
Rivaroxaban—Rash—Pamidronate—osteoporosis	0.000171	0.000773	CcSEcCtD
Rivaroxaban—Dermatitis—Pamidronate—osteoporosis	0.000171	0.000772	CcSEcCtD
Rivaroxaban—Dyspnoea—Estradiol—osteoporosis	0.00017	0.000769	CcSEcCtD
Rivaroxaban—Headache—Pamidronate—osteoporosis	0.00017	0.000768	CcSEcCtD
Rivaroxaban—Diarrhoea—Zoledronate—osteoporosis	0.00017	0.000766	CcSEcCtD
Rivaroxaban—Nausea—Risedronate—osteoporosis	0.00017	0.000766	CcSEcCtD
Rivaroxaban—Pruritus—Conjugated Estrogens—osteoporosis	0.000169	0.000763	CcSEcCtD
Rivaroxaban—Dyspepsia—Estradiol—osteoporosis	0.000168	0.00076	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Estradiol—osteoporosis	0.000165	0.000745	CcSEcCtD
Rivaroxaban—Fatigue—Estradiol—osteoporosis	0.000165	0.000744	CcSEcCtD
Rivaroxaban—Dizziness—Zoledronate—osteoporosis	0.000164	0.000741	CcSEcCtD
Rivaroxaban—Pain—Estradiol—osteoporosis	0.000163	0.000738	CcSEcCtD
Rivaroxaban—Constipation—Estradiol—osteoporosis	0.000163	0.000738	CcSEcCtD
Rivaroxaban—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000163	0.000738	CcSEcCtD
Rivaroxaban—Nausea—Pamidronate—osteoporosis	0.000161	0.000728	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000159	0.00277	CbGpPWpGaD
Rivaroxaban—Dizziness—Conjugated Estrogens—osteoporosis	0.000158	0.000713	CcSEcCtD
Rivaroxaban—Vomiting—Zoledronate—osteoporosis	0.000158	0.000712	CcSEcCtD
Rivaroxaban—Feeling abnormal—Estradiol—osteoporosis	0.000157	0.000711	CcSEcCtD
Rivaroxaban—Rash—Zoledronate—osteoporosis	0.000156	0.000706	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Estradiol—osteoporosis	0.000156	0.000706	CcSEcCtD
Rivaroxaban—Dermatitis—Zoledronate—osteoporosis	0.000156	0.000706	CcSEcCtD
Rivaroxaban—Headache—Zoledronate—osteoporosis	0.000155	0.000702	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CA2—osteoporosis	0.000155	0.0027	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—OXCT1—osteoporosis	0.000155	0.0027	CbGpPWpGaD
Rivaroxaban—Vomiting—Conjugated Estrogens—osteoporosis	0.000152	0.000686	CcSEcCtD
Rivaroxaban—Urticaria—Estradiol—osteoporosis	0.000152	0.000686	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—MGLL—osteoporosis	0.000151	0.00263	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Estradiol—osteoporosis	0.000151	0.000682	CcSEcCtD
Rivaroxaban—Rash—Conjugated Estrogens—osteoporosis	0.000151	0.00068	CcSEcCtD
Rivaroxaban—Dermatitis—Conjugated Estrogens—osteoporosis	0.00015	0.000679	CcSEcCtD
Rivaroxaban—Headache—Conjugated Estrogens—osteoporosis	0.00015	0.000676	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000149	0.0026	CbGpPWpGaD
Rivaroxaban—Nausea—Zoledronate—osteoporosis	0.000147	0.000665	CcSEcCtD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000143	0.00249	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000143	0.00248	CbGpPWpGaD
Rivaroxaban—Nausea—Conjugated Estrogens—osteoporosis	0.000142	0.000641	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—ACE—osteoporosis	0.000141	0.00245	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Estradiol—osteoporosis	0.000141	0.000636	CcSEcCtD
Rivaroxaban—Asthenia—Estradiol—osteoporosis	0.000137	0.000619	CcSEcCtD
Rivaroxaban—Pruritus—Estradiol—osteoporosis	0.000135	0.000611	CcSEcCtD
Rivaroxaban—Diarrhoea—Estradiol—osteoporosis	0.000131	0.000591	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—IDH2—osteoporosis	0.000129	0.00224	CbGpPWpGaD
Rivaroxaban—Dizziness—Estradiol—osteoporosis	0.000126	0.000571	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000122	0.00212	CbGpPWpGaD
Rivaroxaban—Vomiting—Estradiol—osteoporosis	0.000122	0.000549	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000121	0.00211	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP27A1—osteoporosis	0.000121	0.0021	CbGpPWpGaD
Rivaroxaban—Rash—Estradiol—osteoporosis	0.00012	0.000544	CcSEcCtD
Rivaroxaban—Dermatitis—Estradiol—osteoporosis	0.00012	0.000544	CcSEcCtD
Rivaroxaban—Headache—Estradiol—osteoporosis	0.00012	0.000541	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ACP5—osteoporosis	0.000118	0.00205	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	0.000116	0.00202	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000116	0.00201	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000115	0.002	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000114	0.00198	CbGpPWpGaD
Rivaroxaban—Nausea—Estradiol—osteoporosis	0.000114	0.000513	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—TPI1—osteoporosis	0.000109	0.0019	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP19A1—osteoporosis	0.000107	0.00186	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP19A1—osteoporosis	0.000106	0.00184	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—P4HB—osteoporosis	0.000103	0.00179	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GAPDH—osteoporosis	0.000101	0.00176	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—RAP1A—osteoporosis	9.82e-05	0.00171	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	9.47e-05	0.00165	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	9.37e-05	0.00163	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	9.34e-05	0.00163	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IGF1—osteoporosis	9.2e-05	0.0016	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—LEP—osteoporosis	8.75e-05	0.00152	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.57e-05	0.00149	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	8.18e-05	0.00142	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ENO1—osteoporosis	7.94e-05	0.00138	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PSMA5—osteoporosis	7.83e-05	0.00136	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PSMA2—osteoporosis	7.83e-05	0.00136	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	7.66e-05	0.00133	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—POMC—osteoporosis	7.52e-05	0.00131	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—IGF1—osteoporosis	7.23e-05	0.00126	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.94e-05	0.00121	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL1B—osteoporosis	6.71e-05	0.00117	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—POMC—osteoporosis	6.43e-05	0.00112	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	6.42e-05	0.00112	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP19A1—osteoporosis	6.35e-05	0.0011	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PKM—osteoporosis	6.07e-05	0.00106	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—FDPS—osteoporosis	6.07e-05	0.00106	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PGLS—osteoporosis	5.75e-05	0.001	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GPD2—osteoporosis	5.75e-05	0.001	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.63e-05	0.000979	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TGFB1—osteoporosis	5.51e-05	0.000959	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PNP—osteoporosis	5.26e-05	0.000915	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ATIC—osteoporosis	5.26e-05	0.000915	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TGFB1—osteoporosis	5.21e-05	0.000907	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ADCY5—osteoporosis	5.19e-05	0.000903	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GPX1—osteoporosis	5.17e-05	0.0009	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	4.97e-05	0.000866	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	4.96e-05	0.000863	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	4.91e-05	0.000854	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—osteoporosis	4.87e-05	0.000847	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—MTHFR—osteoporosis	4.77e-05	0.00083	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—FDPS—osteoporosis	4.58e-05	0.000796	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PKM—osteoporosis	4.58e-05	0.000796	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—OXCT1—osteoporosis	4.47e-05	0.000778	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CA2—osteoporosis	4.47e-05	0.000778	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MGLL—osteoporosis	4.36e-05	0.000758	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PGLS—osteoporosis	4.34e-05	0.000755	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GPD2—osteoporosis	4.34e-05	0.000755	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	4.29e-05	0.000747	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PNP—osteoporosis	3.97e-05	0.000691	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ATIC—osteoporosis	3.97e-05	0.000691	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—POMC—osteoporosis	3.82e-05	0.000664	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—IDH2—osteoporosis	3.71e-05	0.000645	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP27A1—osteoporosis	3.48e-05	0.000606	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ACP5—osteoporosis	3.39e-05	0.00059	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—OXCT1—osteoporosis	3.37e-05	0.000587	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CA2—osteoporosis	3.37e-05	0.000587	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MGLL—osteoporosis	3.29e-05	0.000572	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TPI1—osteoporosis	3.15e-05	0.000548	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—POMC—osteoporosis	2.99e-05	0.00052	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—P4HB—osteoporosis	2.96e-05	0.000515	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GAPDH—osteoporosis	2.91e-05	0.000506	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RAP1A—osteoporosis	2.83e-05	0.000493	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PKM—osteoporosis	2.82e-05	0.000491	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—FDPS—osteoporosis	2.82e-05	0.000491	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—IDH2—osteoporosis	2.8e-05	0.000487	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PGLS—osteoporosis	2.67e-05	0.000465	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GPD2—osteoporosis	2.67e-05	0.000465	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP27A1—osteoporosis	2.63e-05	0.000457	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.58e-05	0.000449	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.57e-05	0.000448	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ACP5—osteoporosis	2.56e-05	0.000445	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PNP—osteoporosis	2.44e-05	0.000425	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ATIC—osteoporosis	2.44e-05	0.000425	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.41e-05	0.000419	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.4e-05	0.000418	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TPI1—osteoporosis	2.38e-05	0.000414	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ENO1—osteoporosis	2.29e-05	0.000398	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PSMA2—osteoporosis	2.26e-05	0.000392	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PSMA5—osteoporosis	2.26e-05	0.000392	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—P4HB—osteoporosis	2.24e-05	0.000389	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GAPDH—osteoporosis	2.19e-05	0.000382	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RAP1A—osteoporosis	2.14e-05	0.000372	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—OXCT1—osteoporosis	2.08e-05	0.000362	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CA2—osteoporosis	2.08e-05	0.000362	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MGLL—osteoporosis	2.03e-05	0.000353	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP19A1—osteoporosis	1.83e-05	0.000318	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ENO1—osteoporosis	1.73e-05	0.000301	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—IDH2—osteoporosis	1.72e-05	0.0003	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PSMA5—osteoporosis	1.7e-05	0.000296	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PSMA2—osteoporosis	1.7e-05	0.000296	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.62e-05	0.000282	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ACP5—osteoporosis	1.58e-05	0.000274	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ADCY5—osteoporosis	1.5e-05	0.00026	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GPX1—osteoporosis	1.49e-05	0.000259	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TPI1—osteoporosis	1.46e-05	0.000255	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP19A1—osteoporosis	1.38e-05	0.00024	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—P4HB—osteoporosis	1.38e-05	0.00024	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MTHFR—osteoporosis	1.38e-05	0.000239	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GAPDH—osteoporosis	1.35e-05	0.000235	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RAP1A—osteoporosis	1.32e-05	0.000229	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ADCY5—osteoporosis	1.13e-05	0.000196	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GPX1—osteoporosis	1.12e-05	0.000196	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—POMC—osteoporosis	1.1e-05	0.000191	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ENO1—osteoporosis	1.06e-05	0.000185	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PSMA2—osteoporosis	1.05e-05	0.000182	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PSMA5—osteoporosis	1.05e-05	0.000182	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTHFR—osteoporosis	1.04e-05	0.000181	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP19A1—osteoporosis	8.51e-06	0.000148	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—POMC—osteoporosis	8.3e-06	0.000144	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ADCY5—osteoporosis	6.95e-06	0.000121	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GPX1—osteoporosis	6.93e-06	0.000121	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTHFR—osteoporosis	6.39e-06	0.000111	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—POMC—osteoporosis	5.11e-06	8.9e-05	CbGpPWpGaD
